Study protocol: a double blind randomised control trial of high volume image guided injections in achilles and patellar tendinopathy in a young active population by Rob Barker-Davies (1252692) et al.
STUDY PROTOCOL Open Access
Study protocol: a double blind randomised
control trial of high volume image guided
injections in Achilles and patellar
tendinopathy in a young active population
Robert M. Barker-Davies1,2*, Alastair Nicol1, I. McCurdie1, James Watson1, Polly Baker1, Patrick Wheeler2,
Daniel Fong2, Mark Lewis2 and Alexander N. Bennett1
Abstract
Background: Chronic tendinopathy is a significant problem particularly in active populations limiting sporting and
occupational performance. The prevalence of patellar tendinopathy in some sports is near 50% and the incidence
of lower limb tendinopathy is 1.4% p.a. in the UK Military. Management includes isometric, eccentric, heavy slow
resistance exercises and extracorporeal shockwave therapy (ESWT). Often these treatments are inadequate yet there
is no good evidence for injection therapies and success rates from surgery can be as low as 50%.
High Volume Image Guided Injection (HVIGI) proposes to strip away the neovascularity and disrupt the nerve
ingrowth seen in chronic cases and has shown promising results in case series. This study aims to investigate the
efficacy of HVIGI in a randomised controlled trial (RCT).
Methods: RCT comparing 40ml HVIGI, with or without corticosteroid, with a 3ml local anaesthetic sham-control
injection. Ninety-six participants will be recruited. Inclusion criteria: male, 18–55 years old, chronic Achilles or patellar
tendinopathy of at least 6 months, failed conservative management including ESWT, and Ultrasound (US) evidence
of neovascularisation, tendon thickening and echogenic changes. Outcome measures will be recorded at baseline,
6 weeks, 3, 6 and 12 months. Primary outcome measures include The Victoria Institute of Sport Assessments for
Achilles and patellar tendinopathy (VISA-A and VISA-P) and VAS pain. Secondary outcome measures include
Modified Ohberg score, maximum tendon diameter and assessment of hypoechoic appearance on US, and
Functional Activity Assessment.
Discussion: Despite previous interventional trials and reviews there is still insufficient evidence to guide injectable
therapy for chronic tendinopathy that has failed conservative treatment. The scant evidence available suggests
HVIGI has the greatest potential however there is no level one RCT evidence to support this. Investigating the
efficacy of HVIGI against control in a RCT and separating the effect of HVIGI and corticosteroid will add high level
evidence to the management of chronic tendinopathy resistant to conservative treatment.
Trial Registration: EudraCT: 2015-003587-36 3 Dec 2015
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Background
Lower limb tendinopathy is a significant problem espe-
cially in the sporting population. The reported incidence
increases from 1.85/1000 p.a. in the Achilles amongst
the general population to 7.4% per month in marathon
runners [1, 2]. In the patella prevalence is 10–15% in
volleyball and rugby players and up to almost 50% in
masters athletes [3–5]. Military personnel by the nature
of their work are a physically active and sporting popula-
tion. From the UK military Primary Care database inci-
dence of lower limb tendinopathy is estimated at 1.4%
p.a. representing a significant cause of morbidity. This
represents a significant burden to the Armed Forces in
terms of occupational and operational effectiveness. The
unpredictable nature of tendinopathy by virtue of its
poor correlation between pain, function and pathological
stage adds uncertainty to workforce planning and career
development for the individuals affected.
The tendinitis model in use up to the 1990s has been su-
perseded [6]. A continuum model for tendinopathy
whereby abnormal load is seen as the primary cause and
optimal load management is seen as the primary treatment
is now well established and accepted [7]. This model de-
scribed by Cook and Purdam [8] based on histological find-
ings provides the framework on which current best practice
is designed and areas for further research are targeted.
There is increased proteoglycan, ground substance and col-
lagen separation with cells taking on a more chondrotic
shape but absence of typical inflammatory mediators on
traditional histology. Neovascularisation occurs as the path-
ology progresses and is thought to be associated with nerve
ingrowth and pain. With this change of understanding
many treatments have been tried, some with more success
and better evidence than others.
Eccentric Loading Exercise (EL) is a well-established
treatment in Achilles tendinopathy and has been devel-
oped successfully to treat other tendinopathies [9, 10].
Early trials by Alfredson [11, 12] were in older patients
(mean age = 44) with a chronicity that would place them
in the degenerate phase of Cook and Purdam’s continuum.
Unmodified EL is not effective for insertional tendinopa-
thy [13]. Heavy Slow Resistance Exercise (HSR) is an alter-
native to EL. Kongsgaard et al’s [14] RCT investigating
patellar tendinopathy showed similar results for HSR and
EL in terms of pain and function. HSR also yielded in-
creased collagen network turnover and greater satisfaction
than EL in a younger population (mean age = 32).
Extracorporeal Shockwave Therapy (ESWT) showed ini-
tially promising results in supraspinatus, elbow and heel
tendinopathies [15]. Furia’s [16] trial of 68 patients showed
superior results with ESWTcompared to traditional therapy
controls in insertional Achilles tendinopathy. Wang [17] et
al. reported impressive results in favour of ESWT v. control
in patellar tendinopathy with statistically significant
differences in VISA-P scores at 2–3 year follow up. ESWT
has been concluded in reviews by Wiegerinck [18] and van
Leeuwen [19] to be a safe effective treatments for insertional
Achilles and patellar tendinopathies respectively. It should
be noted Zwerver [20] found no effect of ESWT in an RCT
of 62 participants with patellar tendinopathy. Though they
conclude the continued sports participation of mostly react-
ive to disrepair stage tendinopathies treated could explain
the lack of effect and that ESWT may still be effective.
Unfortunately a number of patients still fail to respond
to EL, HSR or ESWT. What to do next is a clinical di-
lemma with insufficient evidence to guide. Surgery re-
mains an option but with success rates as low as 50%
[21] there is a desire to find safe effective treatment that
bridges the gap from conservative management.
High Volume Image Guided Injection (HVIGI) has been
proposed to remove neovascularisation and disrupt nerve
ingrowth [22]. Whilst there is no universally accepted pain
model in tendinopathy there are well established mecha-
nisms for associating angiogenesis with neoneuralisation
including shared genetic pathways and neurotrophic ef-
fects of Vascular Endothelial Growth Factor (VEGF) [23].
Increased substance P positive nerve fibres may provide a
nociceptive stimulus coupled with decreased pain modula-
tion by noradrenaline [24]. Prolonged expression of sub-
stance P may stimulate the hypercellularity and altered
morphology of tenocytes as well as stimulating endothelial
cells [25]. It is anticipated a shearing or compressive effect
of HVIGI by using the neovessels as a target area may
achieve disruption of these nerve fibres. Such mechanical
damage may act synergistically with other mechanisms for
example neurotoxicity and vasoconstriction caused by the
initial local anaesthetic bolus [26].
Table 1 outlines the HVIGI studies to date. The stud-
ies indicate positive results but all lack control groups
and causality of benefit cannot be identified from these
study designs. There is variation in duration of follow up
and the use of corticosteroid (CS) making results of this
group of studies difficult to interpret.
The primary objective of this study therefore is to
identify through a RCT the effectiveness of HVIGI using
injectable saline (40ml) in combination with local anaes-
thetic with/without injected CS compared to a sham-
control injection in patients with chronic tendinopathy
unresponsive to conservative therapies.
The hypotheses are that HVIGI in both the presence
and absence of CS will be superior to control and that
HVIGI without CS will be non-inferior to HVIGI with CS.
Methods/Design
Double blind Randomised Control Trial (RCT)
a. Low volume (3ml) US guided subcutaneous Local
Anaesthetic (LA) sham-control injection.
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or
b. HVIGI: Saline + Local Anaesthetic (LA). Total
volume 40ml.
or
c. HVIGI: Saline + LA + CS. Total volume 40ml.
Participants inclusion/exclusion criteria
Inclusion criteria Male patients with either Achilles
or patellar tendinopathy of at least 6 months chron-
icity who have failed best practice management
(Table 2) including EL, HSR and ESWT aged 18–55
and US evidence of neovascularisation, tendon thick-
ening and echogenic changes will be included in the
study. Patients must be medically unfit for their full
military role. The level of function relating to military
medical grading relates to the patient’s individual role.
The relationship between this and VISA scores will
be explored as part of this research. The diagnostic
guide used for initial diagnosis in primary care is pro-
vided in Table 3. Diagnosis is confirmed by a Sport
and Exercise Medicine Consultant with the additional
US criteria above.
Exclusion criteria Females, patients with a concurrent
alternate lower limb diagnosis, those on anticoagulant
medication or having had previous tendon surgery or
injection to the affected limb will be excluded. Plan-
taris involvement in Achilles tendinopathy will be
treated as an alternate lower limb diagnosis as this is
Table 1 Summary of HVIGI studies
Study Intervention Control +/− VAS
Pain
+/− Function eg VISA-A/P
Achilles tendinopathy
Chan 2008 [68] N = 30
10ml 0.5% Bupivacaine
25mg Hydrocortisone
40ml N Saline
No control N = 21
@4w
-51mm
N = 21
@4w VISA-A +31.4
Humphrey 2010 [69] N = 11
10ml 0.5% Bupivacaine
25mg Hydrocortisone
40ml N Saline
No Control @3w VISA-A +38 (P < 0.001)
NeoVasc reduced 3 to 1.1
Tendon diam 8.7 to 7.6mm
Restighini 2012 [70] N = 32
5ml 1% Lidocaine
25mg Hydrocortisone
Up to 40ml N Saline
No Control @4w
-34mm
@3m
-37mm
@4w VISA-A +26.5
@3m VISA-A +28.7
NeoVasc reduced 2 to 0.2
Maffuli 2013 [71] N = 94
10ml 0.5% Bupivacaine
25mg Aprotinin
up to 40mls N saline
No Control @12m VISA-A +32.9
(P = 0.003)
Wheeler 2014 [72] N = 16
10ml 1% Lidocaine
40ml Saline
No Control @347d −6.1/10
(P = 0.001)
@347d VISA-A + 41
(P = 0.001)
Wheeler 2016 [73] N = 34
10ml 1% Lidocaine +
40ml Saline
V 10ml 1% Lidocaine +
20ml Saline
No Control @281d −4.6/10
(P < 0.01) 50ml Group
@281v271d VISA-A +33.4 and +
6.94 in 50ml and 30ml group
respectively (P = 0.002)
Patellar tendinopathy
Crisp 2008 [74] N = 9
10ml 0.5% Bupivacaine
25mg Hydrocortisone
40ml N Saline
No control @2w
Sig. improve.
@9m VISA-P +22
Morton 2014 [22] N = 20
10 ml 0.5% Bupivacaine
25mg hydrocortisone
30ml N saline
No Control @12w–9m
VISA-P +19
(P < 0.01)
Maffuli 2016 [75] N = 44
10ml 0.5% Bupivacaine
62500 IU Aprotinin
40ml N saline
No Control @15m
-63mm
(P = 0.01)
@15m VISA-P +29.3
(P = 0.003)
VISA-A Victoria Institute of Sport Assessment-Achilles, VISA-P Victoria Institute of Sport Assessment-Patella, VAS Visual Analogue Scale, NeoVasc Grade of Neovascu-
latity, IU International Units, m months, w weeks, d days
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associated with resistance to conservative treatment
and surgery may be more appropriate [27]. Tears and
partial tears will also be treated as alternate
diagnoses.
Follow up
Outcome measures will be taken at baseline and at 6
weeks and 3, 6 and 12 months follow up.
Primary endpoint/outcome
a. The Visual Analogue Scale (VAS) for pain on day of
review at 6 months.
b. Validated Victoria Institute of Sport Assessment-
Achilles (VISA-A) [28] and Victoria Institute of
Sport Assessment-Patella (VISA-P) [29] scores for
pain and function at 6 months.
Table 2 Defence rehabilitation Achilles and Patellar tendinopathy best practice management pathway
Tendon loading
stage
Type of
contraction
Reps/Sets/Holds Aim of phase Progression criteria
Load tolerance tests Outcome
measures
Stage 1 – Low Load
Daily exercise
Isometric (may
avoid painful
range initially)
5x 15–60 s holds
Repeated 4x daily
5 days/week
Inhibit cortical
interpretation of pain.
Tendon adaptation to
load
Able to move body weight double
leg with pain less than 3/10 eg,
squat, calf raise
Numeric Rating
Scale or Visual
Analogue Scale
On first waking
On activity
After activity
VISA A/P
6 weekly
intervals
Stage 2 – Medium
Load
Alternate days with
Stage 1
Eccentric/
Concentric (may
avoid painful
range initially)
3x 10–12
3 s Eccentric / 3 s
Concentric
Inhibit cortical
interpretation of pain
Musculo-tendinous
adaptation to load.
Able to move body weight single
leg with pain less than 3/10, eg
single leg squat/single leg calf raise
Stage 3 – High
Load
Every third day with
Stage 1 and 2 on
days inbetween
Eccentric/
Concentric Heavy
Slow Resistance
3x15 (reduced
progressively as weight
increased)
3 s Eccentric /3 s
Concentric
60% 1RM (3x15 reps)
progressed to 85%
1RM (3x6 reps) in week
12
Musculo-tendinous
adaptation to load
through controlled
movements
Able to perform low level
plyometric test with less than 3/10
pain, eg repeated small hop or split
jump
Eccentric Loading 3x15 (double leg,
single leg, weighted)
Up to 10 s eccentric
phase
Stage 4 – High
Load
In place of Stage 3
loading, with Stage
1 and 2 inbetween
Plyometric Restricted to 60 foot
contacts when
introduced. eg.
3x10 Forward hops
3x10 Single leg hops
Increased to 80 foot
contacts
Elastic loading of
Musculotendinous unit.
Able to perform high level
plyometric test e.g. repeated
maximal hop and multidirectional
hop.
RM Repetition Maximum, VISA-A Victoria Institute of Sport Assessment-Achilles, VISA-P Victoria Institute of Sport Assessment-Patella
Table 3 Diagnostic guide
Achilles tendon (inc Insertional) Patella tendon
Causative factors Common in running sports and may have been precipitated
by a change in training load (volumes, duration or intensity).
Common in running, tabbing and jumping sports and may have
been precipitated by a change in training load (volumes, duration
or intensity).
Pain site Localised tenderness in mid portion of Achilles
(2–6cm from insertion) or at insertion.
Pain at inferior pole of patella.
Pain pattern Pain may occur at start of activity and then ease, or may
increase with duration of activity. Pain after period of rest or
on waking.
Pain may occur at start of activity and then ease, or may increase
with duration of activity. Pain after period of rest or on waking.
Palpation
findings
Localised tenderness in mid portion of Achilles
(2–6cm from insertion) or at insertion.
Focal pain on palpation.
Provocation and
Load Tolerance
Tests
Calf raise
Small hop
Repeated hop
Repeated hop Multidirectional
Maximal forward hop
Leg extension
Single leg decline squat
Small hop
Split jump
Maximal hop
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Secondary endpoints/outcomes
a. VAS for pain on day of review at 6 weeks, 3 and 12
months.
b. VISA-A and VISA-P scores for pain and function at
6 weeks, 3 and 12 months.
c. The degree of neovascularisation measured using
the modified Ohberg Score [30] at 6 weeks, 3
and 6 months. Scoring will be made by one of
the 3 operators delivering injections usually PB
and occasionally AN, and IM if required.
Operators have undertaken training in Ohberg
scoring and demonstrated inter and intra-rater
reliability with Intraclass Correlation Coefficients
of 0.89 and 0.92 respectively. This was achieved
using dynamic US for inter-rater and archived
images for intra-rater reliability in a participant
subset separate from this RCT of 16 symptom-
atic tendons of which 12 had neovascularity.
d. The Functional Activity Assessment (FAA) score
which is validated in the military population [31] at
6 weeks, 3, 6 and 12 months.
e. Strength and balance testing as assessed by study
physiotherapist (JW) at 6 weeks, 3 and 6 months.
This includes the small knee bend score [32] and
5 repetition maximum calf raise and leg extension
for Achilles and patellar tendinopathies
respectively (Table 4). Adherence to the
rehabilitation programme will also be scored using
a percentage measure. This is self-reported by the
participant using a logbook. The study physiother-
apist multiplies out the number of sets and repeti-
tions recorded then divides by the total number
prescribed using this proportion multiplied by 100
to arrive at the final score.
Procedure (Table 5)
As testing and interventions outlined in this study
may be delivered to eligible participants at the first ap-
pointment information will be sent in advance. This will
be done by post providing information sheets. Eligible
patients will be asked to complete the informed consent
form at the first appointment with the consultant per-
forming the intervention. Ineligible patients will con-
tinue to be treated as per current guidelines as will those
that decline study participation.
During the follow up period all participants will be
advised to continue with a home exercise programme.
Physiotherapy treatment will continue at primary care
and Regional Rehabilitation Unit (RRU) level as re-
quired. Oversight of this will be maintained by the
lead physiotherapist at Defence Medical Rehabilitation
Centre (DMRC) Headley Court by providing instruc-
tion to primary care and RRU physiotherapists dir-
ectly to ensure standardisation of post intervention
physiotherapy. All participants will be progressed
along an incremental pathway of rest, isometric, iso-
tonic, EL/HSR and then sport specific activity includ-
ing plyometrics as per Table 2. Participants will be
asked to refrain from seeking alternative treatments
during the trial and to complete an exercise logbook
specific to this study.
Randomisation and blinding procedures
One hundred and eight participants (see power calcula-
tion below) will be allocated in equal proportions across
the 3 intervention arms. 12 batches of 9 envelopes num-
bering 108 envelopes in total with 36 pertaining to each
arm of the study will be prepared and secured in a
locked container held centrally at DMRC. In this
Table 4 5 Repetition maximum testing (5RM)
Step Protocol
1 Patient to adopt relevant exercise position on specific machine – a or b below:
a. Heel raise on leg press through full dorsi/plantarflexion range (Achilles)
b. Knee extension 0–90° (Patella)
2 Estimate a low warm up load that will allow the participant to complete 10
repetitions ensuring they use the full range available
3 Provide a rest period (1–2 min)
4 Estimate a load that will allow the participant to complete 5 repetitions
5 Participant attempts 5 repetitions
6 Provide a rest period (1–2 min)
7 If successful increase load and repeat test
Repeat steps 5–7 until participant unable to complete 5 repetitions or pain
reaches 4/10 or more.
8 Record final load that the participant completed for 5 repetitions
The 5RM provides an objective marker for load capacity of a certain muscle group. Limitation of this test is that weight can only be added by increments that the
machine allows (5Kg/heel raise, 2.5Kg/knee extension). Machine is standardised for every test. Decision to use machines rather than test with free weights is
primarily based on safety. Ideally Isokinetic testing would be preferred but is not available
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manner should the recruited numbers differ participants
will be randomly allocated whilst the proportion of num-
bers across all 3 arms will be equal throughout the data
collection phase.
Once participant eligibility and informed consent are
confirmed, an independent administrator will open one of
the batched envelopes to assign the participant to one arm
of the trial. The treating clinicians including physiothera-
pists and consultants delivering injection interventions
will be blinded to which of the three injections they de-
liver. The Chief Investigator will be informed of which
participants are involved in each trial arm and responsible
for preparation of injection syringes checked by a nurse or
other doctor not involved in the trial. The reception staff
will direct participants to a separate area in the waiting
room where they will be able to complete VAS, VISA and
FAA questionnaires in private. The reception staff will
check the questionnaires for basic errors (eg a missed
page) before filing this in a locked store. The study admin-
istrator will collate these outcome measures on a spread-
sheet designed by the Chief Investigator this will be kept
in a locked store and backed up electronically in a pass-
word protected Microsoft Excel file on the Defence com-
puter network. The Chief Investigator will store hard
copies of the outcome measures in the locked Academic
Department of Military Rehabilitation (ADMR) store and
update a second outcomes spreadsheet so that double
data entry is achieved. A separate store with a list contain-
ing the consecutive trial numbers 1–108 ascribing those
numbers to patient notes numbers and which trial arm
they are in will be maintained by the Chief Investigator
and secured in a locked store within the ADMR. A second
copy of this list will be continually updated and provided
to the Independent Medical Officer who will store this list
in a locked store. This is so that in case of emergency ei-
ther the Chief Investigator or Independent Medical Offi-
cer could be contacted to confirm which treatment a
participant had been given. The DMRC Pharmacy will
also retain hard copies of individual prescriptions as well
as the prescriptions log.
Fully blinding the control injection arm to the clin-
ician is not possible due to the small volume of injectate
(3ml of LA) and difference in procedure; neovessels will
not be targeted under US guidance. The two treatment
arms will be fully blinded to both clinician and partici-
pants, as the volumes delivered will be equal and tech-
nique identical. The steroid to be used does not appear
opaque in the syringe maintaining clinician blinding. Cli-
nicians and participants will be shielded from syringe
preparation. To assess blinding at trial completion par-
ticipants will be asked if they think they were rando-
mised to any individual trial arm, if they think they
received either a HVIGI or control or if they don’t know
which injection they received.
Interventions
Participants will be randomised to receive one of the 3
injections below. Prior to the intervention the clinician
(PB) performs a diagnostic US. As well as other factors
described in the secondary outcomes neovascularity is
identified. Under US guidance a 21G needle is placed
between the anterior aspect of the Achilles tendon and
Kager’s fat pad or posterior aspect of the patella tendon
and Hoffa’s fat pad at the area of maximum neovascular-
isation. Connecting tubing attached with a luer lock to a
10ml syringe is then connected to the needle. Under
Table 5 Patient timeline (Spirit Figure)
Study period
Enrolment Allocation Post-allocation Close-out
Timepoint Referral from RRU First clinic 6w 3m 6m 12m (remote)
Enrolment: X 6m clinic, 12m remote
Eligibility screen X X
Informed consent Written info sent X
Allocation/Random X
Interventions:
RCT Injection X
Progressive Exercise Loading Programme X X X X X
Assessments:
Epidemiology Questionnaire X
VISA, VAS, FAA, X X X X X
USS, Ohberg X X X X
Strength/ Small Knee Bend X X X X
Adherence to Rehabilitation Programme X X X X
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instruction of the clinician the assistant then delivers the
contents of the syringe to separate the fat pad from the
tendon. During the procedure the needle is re-orientated
to ensure maximum separation of the fat pad from the
tendon. A further 10ml syringe then replaces the empty
syringe until 40ml of injectate has been delivered. In
each case the first syringe will contain the LA with/with-
out an additional 0.25ml of CS. Three 10ml syringes of
saline will then follow, followed by a fifth syringe of
2.75–3ml (depending on whether or not the first syringe
contained steroid) to allow for the blind space in the
connecting tubing. In all injections an aseptic technique
will be used. After the procedure the clinician will rescan
the tendon ensuring neovascularity has disappeared.
The Chief Investigator will prescribe in accordance
with current policy approved by the DMRC Medicines
Management Committee by hard copy prescription. A
statement will be entered in the patient notes with ap-
propriate contact details. All participants will receive a
card detailing that they may have been treated with any
of the combinations of medications below:
a. Low volume (3ml) Peritendinous Local Anaesthetic
(LA) Control:
Bupivacaine 0.5%, 3ml = 15mg. Total Volume 3ml
Brand: Marcain Polyamp (Astra Zenica) 0.5%
b. HVIGI Saline (to obliterate neovascularisation on
US) + Local Anaesthetic (LA).
Bupivacaine 0.5%, 10ml = 50mg + Saline 30ml. Total
Volume 40ml
Brand: Marcain Polyamp (Astra Zenica) 0.5% +
Sodium Chloride (Hameln Pharmaceuticals) 0.9%
c. HVIGI Saline (to obliterate neovascularisation on
US) + LA + Corticosteroid (CS).
Bupivacaine 0.5%, 10ml = 50mg + Hydrocortisone
100mg/ml 0.25ml = 25mg + Saline 29.75ml Total
Volume 40ml
Brand: Marcain Polyamp (Astra Zenica) 0.5% +
Efcortesol (Amdipharm UK Limited) 100mg/ml +
Sodium Chloride (Hameln Pharmaceuticals) 0.9%
After completion of the trial details of which com-
bination above was prescribed will be added to the
patient notes.
Study setting
The study will take place entirely at DMRC Headley
Court. This is the MOD’s tertiary referral centre for
Sport Exercise and Rehabilitation Medicine. Patients are
referred to Headley Court as part of routine care.
Recruitment
RRU doctors have been briefed and provided with add-
itional information to have an awareness of this trial and
may suggest referral to DMRC Headley Court once the
physical therapies in the current guidelines and ESWT
have been tried without success. They may mention that
a trial is taking place.
Patient identification
The trial will be mentioned by RRU staff to potential
participants and further information will be provided.
Once a referral has been made the patient will be sent
written information and a copy of the consent form so
that they have a minimum of 24 h to consider the infor-
mation before attending DMRC. It will be stressed that
if patients do not wish to participate in the trial they will
not be prejudiced and will be treated in line with current
best practice. They will still be welcomed to attend
DMRC appointments.
Screening
Patients will be screened as per their normal routine
care for a tertiary referral to DMRC Headley Court.
They will have a 45-min initial appointment with one of
the research team consultants. This will include review-
ing their medical history and checking parameters such
as weight, BMI, pulse and blood pressure. No more inva-
sive tests are required.
Blinding and data access
The Chief Investigator the Independent Medical Officer
and DMRC Pharmacy will have access to the list of
which participant corresponds to which trial number
and which group they have been randomised to.
The treating clinicians will have access to the clinical
record and images on the US machine.
The study administrator, Chief Investigator and ADMR
Manager (Data Monitor) will have access to the original
copies of outcome measure data (Case Report Forms) and
collated results spreadsheets. Should for reasons of lack of
participants the trial need to be declared complete short
of the number identified by power calculation this deci-
sion will be taken in conjunction with MOD and Lough-
borough University supervisors (AB, DF, ML and PW).
Withdrawal criteria
In accordance with the Declaration of Helsinki partici-
pants will be free to withdraw at any time. This trial re-
quires that a single injection only is delivered on the day
of consenting to the trial. Compliance and drop out in
this respect is therefore not anticipated to be a problem.
It is possible that participants may perceive having to
travel and attend follow-up appointments an inconveni-
ence. Under those circumstances further options for
gaining follow up data include its collection at RRU and
failing that primary outcome measures could be assessed
remotely.
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Should the participant no longer wish to participate in
the physical elements of the rehabilitation, which is
current standard practice they are of course free to do so.
A 10% drop out rate has been allowed for (see below).
Sample size
The effect size f has been calculated along with the overall
predicted sample size calculation using GPower (University
of Dusseldorf, GER) [33]. The Minimum Clinically Import-
ant Difference (MCID) in the VISA-P score in athletes with
patellar tendinopathy who underwent conservative man-
agement was calculated by Hernandez-Sanchez [34] to be
12.6 (n = 90 baseline VISA-P = 50.1 (SD = 18.4). The effect
size f of 0.3228096 was combined with an α-level of 0.05
and power of 0.8 in a priori power calculation for an
ANOVA, fixed effects, omnibus one way test predicting an
initial sample size of 96. The calculation was repeated so
that addition of a suspected covariate (percentage adher-
ence to the standardised rehabilitation protocol) could be
considered in ANCOVA again a sample size of 96 was pre-
dicted. Further calculations were made to allow using re-
peated measures, between factors ANOVA assuming
correlation of 0.5 among repeated measures this returned a
smaller total sample sizes of 75 for primary outcome mea-
sures (baseline and 6 month follow-up) and 60 for second-
ary outcome measures (baseline, 6 weeks, 3,6 and 12
month follow-ups). 108 participants with either Achilles or
patellar tendinopathy will be recruited to allow for a 10%
drop out rate.
Statistical analyses
Demographic data over the 3 RCT groups will be com-
pared. This will include the risk factors to be analysed as
part of a correlational study including age, obesity,
smoking, blood group, hypertension and family history.
Parametric assumption checks will be made and one-
way ANOVA used to check for statistical differences that
may have occurred by chance at baseline. Where neces-
sary ANCOVA will be used to correct differences across
the groups. The adherence to rehabilitation score will be
considered as a covariate.
The primary outcome data will be compared between
groups at baseline and 6 months. Individual outcome
measures for each group will be analysed to check para-
metric assumptions. For primary and secondary out-
come measures a repeated measures, between factors
ANOVA (time x intervention) will be used to look for
significant difference. Groups will then be compared
against each other using post hoc pairwise comparisons
using SPSS software and effect sizes calculated.
A protocol deviation log is to be kept so that unantici-
pated trends can be analysed. The proportion of missing
data will be reported with reasons where possible. Missing
data will be handled using multiple imputation calculated
in SPSS. A minimum of 5 imputations will be used. Re-
sults for completed cases will be compared to those based
on multiple imputation and reported in accordance with
the guidance proposed by Sterne et al. [35].
Roles and responsibilities
The role of the Sponsor (Director of Defence Rehabilita-
tion) is to: “Promote effective professional guidelines and
support to medical rehabilitation providers. Develop, pro-
mote and co-ordinate the standardisation and delivery of
best evidence clinical practice across Defence. To support
medical rehabilitation in the operational environment in
order to assist in the maintenance of fighting power. To
provide an inspectorate role across Defence Medical Re-
habilitation. To provide leadership for rehabilitation cadres,
including: Rheumatology & Rehabilitation consultant, Sport
& Exercise Medicine, Physiotherapy, Exercise Rehabilitation
Instruction and other Allied Health Professional groups.
Co-ordination, collection and analysis of medical
intelligence and data related to rehabilitation.”
As the Director of Defence Rehabilitation (DDR) The
Sponsor welcomes this research to further develop the
DDR tendinopathy guidelines. The Sponsor can be con-
tacted via email SGDPHC-DefRehab-DDR@mod.uk.
Given the nature of this research an independent trial
steering committee has not been appointed. An Independ-
ent Medical Officer (IMO) has been appointed to act as a
point of contact outside of the research team. The IMO is
available for patients/participants and staff members who
may have any questions or concerns that might not neces-
sitate the significant event reporting process.
The Trial Management Group meets at least quarterly
and consists of the authors listed above.
This protocol has been reviewed and approved by the:
The Defence Medical Services Research Steering Group,
The Surgeon General’s Higher Degree Board, The Dean of
the School of Sport, Exercise and Health Sciences, Lough-
borough University, The Defence Science and Technology
Laboratory’s Scientific Assessment Committee, MODREC
with acceptance of this approval by LU ethics committee
and the MHRA. Amendments suggested by these bodies
have been incorporated into this protocol.
Monitoring
An Independent Data Monitoring Committee (IDMC)
has been appointed in accordance with National Re-
search Ethics Service guidance [36] and the DAMO-
CLES study group recommendations [37]. Members are
the clinical research manager of ADMR, the chair of the
DMRC Medicines Management Committee, the DMRC
Clinical Quality Manager and an Independent statisti-
cian. The Chief Investigator will analyse and make avail-
able accruing data, the protocol deviation log and
significant event reports prior to the IDMC meeting 6
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monthly. The ADMR manager will inspect all locked
stores containing Case Report Forms and audit transfer
to results spreadsheets monthly. As set out in its charter
the IDMC makes recommendations to the Sponsor who
retains executive decision-making on trial stopping.
Safety reporting
All Significant Adverse Events and Suspected Unexpected
Serious Adverse Reactions (SAEs/SUSARs) occurring
from the time of written informed consent and start of
trial treatment until 6 months post cessation of trial treat-
ment and discharge from the care of DMRC Headley
Court must be recorded on a reporting form and the
Sponsor notified within 24 h of the research staff becom-
ing aware of the event. Full details, duration, action taken,
outcome, seriousness criteria, causality and expectedness
will be collected. Any change of condition or other follow-
up information should be made available to the Sponsor
via the DMRC Clinical Quality Manager as soon as it is
available or at least within 24 h of the information becom-
ing available. Events will be followed up until the event
has resolved or a final outcome has been reached.
All SAEs assigned by the CI or delegate (or following
central review) as both suspected to be related to IMP-
treatment and unexpected will be classified as SUSARs
and will be subject to expedited reporting to the Medi-
cines and Healthcare Products Regulatory Agency
(MHRA). The Sponsor will inform the MHRA, the REC
and the Sponsor of SUSARs within the required expe-
dited reporting timescales. If any urgent safety measures
are taken the CI/Sponsor they shall immediately and in
any event no later than 3 days from the date the mea-
sures are taken, give written notice to the MHRA and
the relevant REC of the measures taken and the circum-
stances giving rise to those measures.
Governance and dissemination of results
In accordance with Good Clinical Practice (GCP) guid-
ance personally identifiable information will only be
available on the enrolment log which is kept in a locked
store as part of the trial master file. All other source
documents will be identified using the unique partici-
pant trial number and initials.
As described above only the study administrator, Chief
Investigator and ADMR manager will have immediate
access to the full dataset during the trial. The IDMC will
be able to review accrued data 6 monthly and it is stipu-
lated in their charter not to discuss these results prior to
completion of the trial. In accordance with the Defence
Rehabilitation – Transfer of Research Findings into Best
Practice algorithm the Chief Investigator will complete
the trial report. The report will then be forwarded to the
Defence Director of Rehabilitation’s (DDR) Clinical Pol-
icy Committee (CPC) for consideration. The CPC Chair
(DDR) will then instruct the Best Practice Guideline
Chair to review the findings. The Best Practice Guideline
Chair and Chief Investigator will together prepare up-
dated guidelines for submission to the CPC for approval.
The CPC will also recommend the original report be ap-
proved for publication. This manuscript will be subject
to approval by The Surgeon General’s Director of Re-
search and the Commanding Officer of DMRC Headley
Court. Publication will be sought in a relevant peer re-
view journal with as high an impact factor as possible.
Loughborough University will be acknowledged for their
support in this research. The Chief Investigator’s final
report will also be submitted to Loughborough Univer-
sity in the format of a PhD thesis. The MOD retains
ownership and rights to publish the data. Results in lay
terms will be made available to participants. All reports
are to be written up no later than 12 months following
completion of the trial. The research team listed as au-
thors to this protocol will be included as authors on re-
search publications arising from this trial. The Chief
Investigator will be first author. Professional medical
writers will not be hired. Additional advice may be
sought on the areas of statistics and biomechanical ana-
lysis and should significant contribution be made those
parties listed as authors. The full protocol and partici-
pant level data set may be requested from the Chief In-
vestigator. Trial participants in accordance with The
Declaration of Helsinki 2013 will have access to any
treatments shown to be beneficial at the end of the trial
that remain appropriate for them on medical grounds.
As the tertiary referral centre for Rehabilitation in the
Armed Forces DMRC Headley Court will continue to
care for these patients where appropriate. A research
participant wishing to seek no-fault compensation
should contact the DBR Common Law Claims & Policy
(CLCP), Ministry of Defence, Level 1, Spine 3, Zone J,
Whitehall, London, SW1A 2HB.
Discussion
Kearney’s Cochrane review of all injection therapies in
Achilles tendinopathy found insufficient evidence to rec-
ommend any individual therapy and recommended that
injections should take place in a research setting [38].
Other than HVIGI covered above options include CS,
Autologous Blood (AB), Platelet Rich Plasma (PRP),
Dextrose and polidocanol.
Traditionally CS injection was commonplace but with
the demise of the tendinitis model and case reports of
tendon rupture [39, 40] its use has become less popular.
Coombes et al’s [41] systematic review of RCTs found of
the trials that reported adverse effects only one in 991
participants suffered tendon rupture following CS injec-
tion. They found CS to be effective in the short term but
to have no benefit at intermediate or long term follow
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up. Kongsgaard et al.[14] examined the tissue biopsy
samples post steroid injection and found mechanical
properties to be unaffected.
Rees et al. [42] make a case for re-visiting inflamma-
tion. They highlight that more recent research tech-
niques have demonstrated the presence of inflammatory
mediators such as macrophage derived IL-1, COX-1,
COX-2, IL-6, TGF-β and Substance-P. Whilst acknow-
ledging that mechanical overload remains the primary
driver initiating tendinopathy they call for emphasis on
treatments that address these elements of inflammation.
Therefore there may then still be a place for CS injection
in combination with the evidence-based physical therap-
ies discussed above. US guidance to confirm peritendi-
nous rather than intratendinous injection may also
mitigate risks further [43]. CS appears to be useful for
short-term symptom improvement rather than the sus-
tained improvement to the underlying pathology. A
RCT investigating HVIGI treatment with or without CS
has yet to be published.
Dextrose is proposed to cause a local inflammatory
reaction and injected intratendinously. Dextrose has
shown promising results in case series in patellar [44]
and Achilles [45, 46] tendinopathy but is yet to be re-
ported against control in these tendons. Although these
studies report no adverse effects Knobloch highlights
the potential for increased tendon hypoxia and infec-
tion due to the intratendinous placement of the agent
[47]. In contrast polidocanol is injected peripheral to
the tendon to sclerose the neovascularity thus mitigat-
ing these risks [48]. In patellar tendinopathy polidoca-
nol has shown significant improvement against control
in a RCT [49]. However in contrast to HVIGI both dex-
trose and polidocanol usually require repeat injections.
In the case of polidocanol in Hoksrud’s RCT the mean
number of injections, which are considered difficult to
perform, was 3.6 ± 1.5 in the treatment group over 8
months. The control group (n = 16) was also crossed
over to the intervention after 4 months at which stage
the improvement in the treatment group was less than
the MCID mentioned above [49].
AB/PRP injections in theory deliver an intratendinous
stimulus of growth factors to correct failed healing [50]
in the form of whole blood or centrifuged platelets. Early
small trials with no control arms showed positive results
[51–56]. Creaney et al. is the largest such study and
compares AB with PRP finding no significant difference
between the two [57]. Of AB/PRP trials using active
treatments as comparators results are mixed with differ-
ent methodologies [58–62]. Three RCTs comparing PRP
with saline showed no effect [63–65]. Moraes’ Cochrane
review of PRP identified only 19 eligible papers for inclu-
sion and concluded there was insufficient evidence for
the effect of PRP [66].
Despite much debate and a number of interventional
trials and reviews it is still unclear what is the best in-
jectable therapy to use in patients with chronic tendino-
pathy that has failed conservative treatment. The lack of
long-term effect of CS, need for repeated injections with
dextrose and polidocanol and need for centrifuge equip-
ment combined with the strong evidence against AB/
PRP point towards HVIGI as a potential superior option.
However many HVIGI papers are by the same group in-
dicating that the proposed successes may be operator
dependent and to date there have been no RCTs. Fre-
quently innovative sports medicine procedures have be-
come commonplace without sufficient evidence and at
high risk of bias [67]. The lack of properly designed
RCTs relating to HVIGI and providing evidence for the
separate effect of HVIGI and CS, two different mecha-
nisms of action, needs to be addressed and is vital to fur-
ther the clinical use of injectable therapies in the
management of chronic tendinopathy.
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